Merit and Demerit of Polyvalent Snake Antivenoms

References

• Bogarin G., Segura E., Duran G., Lomonte B., Rojas G., Gutierrez J. M. Evaluation of neutralizing ability of four commercially available antivenoms against the venom of Bothrops asper from Costa Rica. Toxicon 1995; 33: 1242–1247
   PubMed Web of Science ®Google Scholar
• Boquet P. Immunological properties of snake venoms. Snake Venoms, C. Y. Lee. Springer, Berlin 1979; 751–824
   Google Scholar
• Braz A., Minozzo J., Abreu J. C., Gubert I. C., Chavez‐Olortegui C. Development and evaluation of the neutralizing capacity of horse antivenom against the Brazilian spider Loxosceles intermedia. Toxicon 1999; 37: 1323–1328
   PubMed Web of Science ®Google Scholar
• Chinonavanig L., Billings P. B., Matangkasombut P., Ratanabanangkoon K. Antigenic relationships and relative immunogenicities of venom proteins of six poisonous snakes of Thailand. Toxicon 1988; 26: 883–890
   PubMed Web of Science ®Google Scholar
• Chippaux J. P., Goyffon M. Production and use of snake antivenin. Handbook of Natural Toxins, A. T. Tu. Marcel Dekker, New York 1991; Vol. 5: 529–555
   Google Scholar
• Chippaux J. P., Goyffon M. Venoms, antivenoms and immunotherapy. Toxicon 1998; 36: 823–846
   PubMed Web of Science ®Google Scholar
• Chippaux J. P., Lang J., Eddine S. A., Fagot P., Rage V., Peyrieux J. C., Le Mener V. Clinical safety of a polyvalent F(ab′)2 equine antivenom in 223 African snake envenomations: a field trial in Cameroon. VAO (Venin Afrique de l'Ouest) Investigators. Trans. R. Soc. Trop. Med. Hyg. 1998; 92: 657–662
   PubMed Web of Science ®Google Scholar
• Chippaux J. P., Lang J., Amadi‐Eddine S., Fagot P., Le Mener V. Short report: treatment of snake envenomations by a new polyvalent antivenom composed of highly purified F(ab)2: results of a clinical trial in northern Cameroon. Am. J. Trop. Med. Hyg. 1999; 61: 1017–1018
   PubMed Web of Science ®Google Scholar
• Chotwiwatthanakun C., Pratanaphon R., Akesowan S., Sriprapat S., Ratanabanangkoon K. Production of potent polyvalent antivenom against three elapid venoms using a low dose, low volume, multi‐site immunization protocol. Toxicon 2001; 39: 1487–1494
   PubMed Web of Science ®Google Scholar
• Christensen P. A. Production and standardization of antivenin. Snake Venoms, C. Y. Lee. Springer, Berlin 1979; 825–846
   Google Scholar
• Coetzer P. W.W., Tilburg C. R. The epidemiology of snakebite in northern Natal. S. Afr. Med. J. 1982; 62: 206–212
   PubMed Web of Science ®Google Scholar
• Coulter A. R., Harris R. D., Sutherland S. K. Enzyme immunoassay for the rapid clinical identification of snake venom. Med. J. Aust. 1980; 1: 433–435
   PubMed Web of Science ®Google Scholar
• dos Santos M. C., D'Imperio M. R., Furtodo G. C., Colletto G. M.D.D., Kipnis T. L., Dias da Silva W. Purification of F(ab′)2 anti‐snake venom by caprylic acid: a fast method for obtaining IgG fragments with high neutralization activity, purity and yield. Toxicon 1989; 27: 297–303
   PubMed Web of Science ®Google Scholar
• Ganthavorn S. Toxicities of Thailand snake venoms and neutralization capacity of antivenin. Toxicon 1969; 7: 239–241
   PubMed Web of Science ®Google Scholar
• Gingrich W. C., Hohenadel J. C. Standardization of polyvalent antivenins. Venoms. A.A.A.S., Washington, DC 1956
   Google Scholar
• Gutierrez J. M., Gene J. A., Rojas G., Cerdas L. Neutralization of proteolytic and hemorrhagic activities of Costa Rican snake venoms by a polyvalent antivenom. Toxicon 1985; 23: 887–893
   PubMed Web of Science ®Google Scholar
• Karlson‐Stiber C., Persson H., Heath A., Smith D., Al‐Abdulla I. H., SyÖstrom L. First clinical experiences with specific sheep Fab fragments in snake bite. Report of a multicenter study of Vipera berus envenoming. J. Int. Med. 1997; 241: 53–58
   PubMed Web of Science ®Google Scholar
• Kittigul L., Ratanabanangkoon K. Reverse passive hemagglutination tests for rapid diagnosis of snake venoms. J. Immunoassay 1993; 14: 105–127
   PubMedGoogle Scholar
• Kornalik F., Taborska E. Cross reactivity of mono‐ and polyvalent antivenoms with Viperidae and Crotalidae snake venoms. Toxicon 1989; 27: 1135–1142
   PubMed Web of Science ®Google Scholar
• Kukongviriyapan V., Poopyruchpong N., Ratanabanangkoon K. Some parameters of affinity chromatography in the purification of antibody against Naja naja siamensis Toxin 3. J. Immunol. Methods 1982; 49: 97–104
   PubMed Web of Science ®Google Scholar
• Malasit P., Warrell D. A., Chanthavanich P., Viravan C., Mongkolsapaya J., Singhthong B., Supich C. Prediction, prevention and mechanism of early (anaphylactic) antivenom reactions in victims of snake bites. Br. Med. J. 1986; 292: 17–20
   PubMed Web of Science ®Google Scholar
• Mebs D. Myotoxic activity of phospholipases A2 isolated from cobra venoms: neutralization by polyvalent antivenoms. Toxicon 1986; 24: 1001–1008
   PubMed Web of Science ®Google Scholar
• Mebs D., Pohlmann S., Von Tenspolde W. Snake venom hemorrhagins: neutralization by commercial antivenoms. Toxicon 1988; 26: 453–458
   PubMed Web of Science ®Google Scholar
• Meyer W. P., Habib A. G., Onayade A. A., Yakubu A., Smith D. C., Nasidi A., Daudu I. J., Warrell D. A., Theakston R. D.G. First clinical experiences with a new Fab Echis ocellatus snake bite antivenom in Nigeria: randomized comparative trial with Institute Pasteur Serum (IPSER) Africa antivenom. Am. J. Trop. Med. Hyg. 1997; 56: 291–300
   PubMed Web of Science ®Google Scholar
• Minton S. A., Jr. Common antigens in snake venoms. Snake Venoms, C. Y. Lee. Springer, Berlin 1979; 847–862
   Google Scholar
• Mohamed A. H., Bakr I. R., Kamel A. Egyptian polyvalent anti‐snake bite serum; technique of preparation. Toxicon 1966; 4: 69–72
   PubMed Web of Science ®Google Scholar
• Moran N. F., Newman W. J., Theakston R. D., Warrell D. A., Wilkinson D. High incidence of early anaphylactoid reaction to SAIMR polyvalent snake antivenom. Trans. R. Soc. Trop. Med. Hyg. 1998; 92: 69–70
   PubMed Web of Science ®Google Scholar
• Offerman S. R., Smith T. S., Derlet R. W. Does the aggressive use of polyvalent antivenin for rattlesnake bites result in serious acute side effects?. West. J. Med. 2001; 175: 88–91
   PubMedGoogle Scholar
• Otero R., Nunez V., Osorio R. G., Gutierrez J. M., Giraldo C. A., Posada L. E. Ability of six Latin American antivenoms to neutralize the venom of mapana equis (Bothrops atrox) from Antioquia and Choco (Colombia). Toxicon 1995; 33: 809–815
   PubMed Web of Science ®Google Scholar
• Otero R., Gutierrez J. M., Nunez V., Robles A., Estrada R., Segura E., Toro M. F., Garcia M. E., Diaz A., Ramirez E. C., Gomez G., Castaneda J., Moreno M. E. A randomized double‐blind clinical trial of two antivenoms in patients bitten by Bothrops atrox in Colombia. The Regional Group on Antivenom Therapy Research (REGATHER). Trans. R. Soc. Trop. Med. Hyg. 1996; 90: 696–700
   PubMed Web of Science ®Google Scholar
• Pratanaphon R., Akesowan S., Khow O., Sriprapat S., Ratanabanangkoon K. Production of highly potent horse antivenom against the Thai cobra (Naja kaouthia). Vaccine 1997; 15: 1523–1528
   PubMed Web of Science ®Google Scholar
• Pross H. F., Eidinger D. Antigenic competition: a review of non‐specific antigen‐induced suppression. Adv. Immunol. 1974; 18: 133–168
   PubMedGoogle Scholar
• Rojas G., Jimenez J. M., Gutierrez J. M. Caprylic acid fractionation of hyperimmune horse plasma: description of a simple procedure for antivenom production. Toxicon 1994; 32: 351–363
   PubMed Web of Science ®Google Scholar
• Sells P. G., Jones R. G., Laing G. D., Smith D. C., Theakston R. D. Experimental evaluation of ovine antisera to Thai cobra (Naja kaouthia) venom and its alpha‐neurotoxin. Toxicon 1994; 32: 1657–1665
   PubMed Web of Science ®Google Scholar
• Smith D. C., Krisana R. R., Laing G., Theakston R. G.D., Landon J. An affinity purified ovine antivenom for the treatment of Vipera berus envenoming. Toxicon 1992; 30: 865–871
   PubMed Web of Science ®Google Scholar
• Songsumard S. Snakebite in Thailand. Annual Epidemiology Surveillance Report. Ministry of Public Health. 1995; 324–333
   Google Scholar
• Sunthornandh P., Matangkasombut P., Ratanabanangkoon K. Preparation, characterization and immunogenicity of various polymers and conjugates of elapid post‐synaptic neurotoxins. Mol. Immunol. 1992; 29: 501–510
   PubMed Web of Science ®Google Scholar
• Tan N. H., Choy S. K., Chin K. M., Ponnudurai G. Cross‐reactivity of monovalent and polyvalent Trimeresurus antivenoms with venoms from various species of Trimeresurus (lance‐headed pit viper) snake. Toxicon 1994; 32: 849–853
   PubMed Web of Science ®Google Scholar
• Theakston R. D., Laing G. D., Fielding C. M., Lascano A. F., Touzet J. M., Vallejo F., Guderian R. H., Nelson S. J., Wuster W., Richards A. M. Treatment of snake bites by Bothrops species and Lachesis muta in Ecuador: laboratory screening of candidate antivenoms. Trans. R. Soc. Trop. Med. Hyg. 1995; 89: 550–554
   PubMed Web of Science ®Google Scholar
• Weinstein S. A., Schmidt J. J., Smith L. A. Protein lethal toxins and cross‐neutralization of venoms from the African water cobras, Boulengerina annulata annulata and Boulengerina christyi. Toxicon 1991; 29: 1315–1327
   PubMed Web of Science ®Google Scholar
• White J. Envenoming and antivenom use in Australia. Toxicon 1998; 36: 1483–1492
   PubMed Web of Science ®Google Scholar